As indicated, despite the tumor-promoting effects of many growth factors and peptides (Sikiric et al., 2018), BPC 157 has been shown to inhibit and counteract uncontrolled cell proliferation (Ki-67 overproduction counteracted) and increased expression of VEGF and subsequent signaling pathways (Radeljak et al., 2004
The specific concerns were not fully detailed publicly but likely related to the limited US-standard clinical trial data and the peptide's widespread use exceeding the evidence base recognized by FDA standards
For most peptides, the PK and PD timescales are tightly linked: when serum concentration falls, effect diminishes
There are no major human clinical trials that have evaluated the safety or efficacy of BPC 157
In general, Wegovy should be stored in the refrigerator
Human mental health data for BPC-157 is very limited